Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-Risk TAVR Trial Shows Low Mortality at 1 Year

Key clinical point: Anticipating pivotal trials due next week at ACC, investigator-led study shows excellent TAVR results in low risk patients.

Major finding: At one year, cardiovascular-related mortality was 1% and there were no disabling strokes.

Data Source: Investigator-led non-randomized study.

Disclosures: Dr. Waksman reports financial relationships with numerous manufacturers of devices for interventional cardiology including those that produce TAVR devices.

Citation:

2019 Cardiovascular Research Technologies.

This Week's Must Reads

CVD Event Rates Among Adults with PCSK9 Inhibition, Cardiovasc Drugs Ther; ePub 2019 Feb 11; Colantonio, et al

Statin Adherence & Mortality in Patients with ASCVD, JAMA Cardiol; ePub 2019 Feb 13; Rodriguez, et al

Physician Monitoring & LDL-C Follow-Up Testing , Prev Med; 2019 Apr; Dansinger, Williams, et al

CVD Prevalence in HeFH After Statin Treatment, Atherosclerosis; ePub 2019 Feb 12; Perez-Calahorra, et al

Must Reads in Interventional Cardiology & Surgery

Stroke endovascular therapy: The more you do, the better you do, Sheth SA et al. ISC 2019, Abstract 002

High Bleeding Risk & DES Use in ACS Patients, Am J Cardiol; ePub 2017 Jul 24; Alraies, et al

FDA Approves Avalus Surgical Aortic Valve, Medtronic news release; 2017 Aug 2

FDA Approves Recapturable TAVR System, Medtronic news release; 2016 Oct 26